The use of stents has improved management and outcomes of coronary artery disease, and clinical trials are attempting to prove the same will be true for superficial femoral artery disease. Randomized trials have shown favorable results for self-expanding nitinol stents compared with balloon angioplasty. A new report seeks to test this treatment in a real-world population of patients enrolled in an observational registry.

Cigna Corporation has reinstated coverage of the Ambulatory Cardiac Telemetry (ACT) service and is retroactively effective as of June 15, 2014.

Lombard Medical Inc., a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA), today announced that its lead product, Aorfix, an endovascular stent graft to treat AAA, has received approval from the Japanese Ministry of Health, Labour and Welfare. Commercial sales will follow reimbursement approval. Aorfix will be exclusively distributed by Medico's Hirata Inc. Japan is the world’s second-largest standalone EVAR market.

The Cardiovascular Cell Therapy Research Network (CCTRN) has selected Cytori Therapeutics Inc. to supply adipose-derived regenerative cells (ADRC) for a clinical trial aimed at evaluating the safety and feasibility of treating patients with left ventricular assist devices (LVADs). The CCTRN is supported by grants from the National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). This trial, named CELLVAD-ADRC, will explore outcomes following administration of a regenerative cell preparation from adipose tissue into the patient’s heart muscle 60 to 90 days after placement of an LVAD.

Healthcare organizations looking to implement low dose protocols for computed tomography (CT) exams on all scanners, regardless of disparate locations, can now benefit from SafeCT Enterprise from Medic Vision. The solution will be displayed at RSNA 2014.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now